Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
fb-PMT in Recurrent Glioblastoma
NCT05226494Phase 1Active, not recruiting
- Sponsor
- NanoPharmaceuticals LLC
- Start
- Jun 2022
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fb-PMT in glioblastoma (GBM), sponsored by NanoPharmaceuticals LLC. Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 15 months and Incidence of Dose Limiting Toxicities at 28 days. Started Jun 2022; status: active, not recruiting.
02
Drugs
fb-PMT
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT05226494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05226494.